Literature DB >> 24356968

Dysregulated D-dopachrome tautomerase, a hypoxia-inducible factor-dependent gene, cooperates with macrophage migration inhibitory factor in renal tumorigenesis.

Vinay Pasupuleti1, Weinan Du, Yashi Gupta, I-Ju Yeh, Monica Montano, Cristina Magi-Galuzzi, Scott M Welford.   

Abstract

Clear cell renal cell carcinomas (ccRCCs) are characterized by biallelic loss of the von Hippel-Lindau tumor suppressor and subsequent constitutive activation of the hypoxia-inducible factors, whose transcriptional programs dictate major phenotypic attributes of kidney tumors. We recently described a role for the macrophage migration inhibitory factor (MIF) in ccRCC as an autocrine-signaling molecule with elevated expression in tumor tissues and in the circulation of patients that has potent tumor cell survival effects. MIF is a pleiotropic cytokine implicated in a variety of diseases and cancers and is the target of both small molecule and antibody-based therapies currently in clinical trials. Recent work by others has described D-dopachrome tautomerase (DDT) as a functional homologue of MIF with a similar genomic structure and expression patterns. Thus, we sought to determine a role for DDT in renal cancer. We find that DDT expression mirrors MIF expression in ccRCC tumor sections with high correlation and that, mechanistically, DDT is a novel hypoxia-inducible gene and direct target of HIF1α and HIF2α. Functionally, DDT and MIF demonstrate a significant overlap in controlling cell survival, tumor formation, and tumor and endothelial cell migration. However, DDT inhibition consistently displayed more severe effects on most phenotypes. Accordingly, although dual inhibition of DDT and MIF demonstrated additive effects in vitro, DDT plays a dominant role in tumor growth in vivo. Together, our findings identify DDT as a functionally redundant but more potent cytokine to MIF in cancer and suggest that current attempts to inhibit MIF signaling may fail because of DDT compensation.

Entities:  

Keywords:  Cancer Biology; Clear Cell Renal Cell Carcinoma; DDT; Gene Regulation; Hypoxia; Hypoxia-inducible Factor (HIF); Kidney; MIF; VHL; von Hippel-Lindau

Mesh:

Substances:

Year:  2013        PMID: 24356968      PMCID: PMC3916569          DOI: 10.1074/jbc.M113.500694

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

Review 1.  Hypoxia-inducible factors in physiology and medicine.

Authors:  Gregg L Semenza
Journal:  Cell       Date:  2012-02-03       Impact factor: 41.582

Review 2.  Hypoxia in cancer: significance and impact on clinical outcome.

Authors:  Peter Vaupel; Arnulf Mayer
Journal:  Cancer Metastasis Rev       Date:  2007-06       Impact factor: 9.264

Review 3.  Role of MIF in inflammation and tumorigenesis.

Authors:  Jan-Philipp Bach; Birgit Rinn; Bernhard Meyer; Richard Dodel; Michael Bacher
Journal:  Oncology       Date:  2008-09-15       Impact factor: 2.935

4.  The cytokine macrophage migration inhibitory factor reduces pro-oxidative stress-induced apoptosis.

Authors:  Mai Tuyet Nguyen; Hongqi Lue; Robert Kleemann; Michael Thiele; Gabriele Tolle; Doris Finkelmeier; Eva Wagner; Andrea Braun; Jürgen Bernhagen
Journal:  J Immunol       Date:  2003-03-15       Impact factor: 5.422

5.  Comparative light and electron microscopic observations of the cytoplasmic matrix in renal carcinomas.

Authors:  J L Ericsson; R Seljelid; S Orrenius
Journal:  Virchows Arch Pathol Anat Physiol Klin Med       Date:  1966-10-10

6.  Role of macrophage migration inhibitory factor in primary glioblastoma multiforme cells.

Authors:  Nina Baron; Oliver Deuster; Carmen Noelker; Carsten Stüer; Herwig Strik; Carlo Schaller; Richard Dodel; Bernhard Meyer; Michael Bacher
Journal:  J Neurosci Res       Date:  2011-02-24       Impact factor: 4.164

7.  Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity.

Authors:  H Lue; M Thiele; J Franz; E Dahl; S Speckgens; L Leng; G Fingerle-Rowson; R Bucala; B Lüscher; J Bernhagen
Journal:  Oncogene       Date:  2007-02-19       Impact factor: 9.867

8.  Negative regulation of AMP-activated protein kinase (AMPK) activity by macrophage migration inhibitory factor (MIF) family members in non-small cell lung carcinomas.

Authors:  Stephanie E Brock; Beatriz E Rendon; Kavitha Yaddanapudi; Robert A Mitchell
Journal:  J Biol Chem       Date:  2012-09-17       Impact factor: 5.157

Review 9.  The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer.

Authors:  William G Kaelin
Journal:  Nat Rev Cancer       Date:  2008-10-16       Impact factor: 60.716

10.  Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.

Authors:  Dan Huang; Yan Ding; Yan Li; Wang-Mei Luo; Zhong-Fa Zhang; John Snider; Kristin Vandenbeldt; Chao-Nan Qian; Bin Tean Teh
Journal:  Cancer Res       Date:  2010-01-26       Impact factor: 12.701

View more
  20 in total

1.  Structural Plasticity in the C-Terminal Region of Macrophage Migration Inhibitory Factor-2 Is Associated with an Induced Fit Mechanism for a Selective Inhibitor.

Authors:  Georgios Pantouris; Richard Bucala; Elias J Lolis
Journal:  Biochemistry       Date:  2018-06-12       Impact factor: 3.162

2.  Autophagic flux is essential for the downregulation of D-dopachrome tautomerase by atractylenolide I to ameliorate intestinal adenoma formation.

Authors:  Lu Li; Linlin Jing; Junjiang Wang; Wenjuan Xu; Xianling Gong; Yiye Zhao; Ye Ma; Xueqing Yao; Xuegang Sun
Journal:  J Cell Commun Signal       Date:  2018-01-24       Impact factor: 5.782

3.  Cardiomyocyte d-dopachrome tautomerase protects against heart failure.

Authors:  Yina Ma; Kevin N Su; Daniel Pfau; Veena S Rao; Xiaohong Wu; Xiaoyue Hu; Lin Leng; Xin Du; Marta Piecychna; Kenneth Bedi; Stuart G Campbell; Anne Eichmann; Jeffrey M Testani; Kenneth B Margulies; Richard Bucala; Lawrence H Young
Journal:  JCI Insight       Date:  2019-09-05

4.  A selective small-molecule inhibitor of macrophage migration inhibitory factor-2 (MIF-2), a MIF cytokine superfamily member, inhibits MIF-2 biological activity.

Authors:  Pathricia Veronica Tilstam; Georgios Pantouris; Michael Corman; Monica Andreoli; Keyvan Mahboubi; Gary Davis; Xin Du; Lin Leng; Elias Lolis; Richard Bucala
Journal:  J Biol Chem       Date:  2019-10-02       Impact factor: 5.157

Review 5.  Stromal-dependent tumor promotion by MIF family members.

Authors:  Robert A Mitchell; Kavitha Yaddanapudi
Journal:  Cell Signal       Date:  2014-09-30       Impact factor: 4.315

6.  Endothelial CD74 mediates macrophage migration inhibitory factor protection in hyperoxic lung injury.

Authors:  Maor Sauler; Yi Zhang; Jin-Na Min; Lin Leng; Peiying Shan; Scott Roberts; William L Jorgensen; Richard Bucala; Patty J Lee
Journal:  FASEB J       Date:  2015-01-21       Impact factor: 5.191

7.  Targeting distinct tautomerase sites of D-DT and MIF with a single molecule for inhibition of neutrophil lung recruitment.

Authors:  Deepa Rajasekaran; Swen Zierow; Mansoor Syed; Richard Bucala; Vineet Bhandari; Elias J Lolis
Journal:  FASEB J       Date:  2014-07-11       Impact factor: 5.191

8.  D-dopachrome tautomerase activates COX2/PGE2 pathway of astrocytes to mediate inflammation following spinal cord injury.

Authors:  Huiyuan Ji; Yuxin Zhang; Chen Chen; Hui Li; Bingqiang He; Ting Yang; Chunshuai Sun; Huifei Hao; Xingyuan Zhang; Yingjie Wang; Yue Zhou; Zhenjie Zhu; Yuming Hu; Aihong Li; Aisong Guo; Yongjun Wang
Journal:  J Neuroinflammation       Date:  2021-06-11       Impact factor: 8.322

Review 9.  CD74 in Kidney Disease.

Authors:  Lara Valiño-Rivas; Ciro Baeza-Bermejillo; Laura Gonzalez-Lafuente; Ana Belen Sanz; Alberto Ortiz; Maria Dolores Sanchez-Niño
Journal:  Front Immunol       Date:  2015-09-23       Impact factor: 7.561

10.  MIF family members cooperatively inhibit p53 expression and activity.

Authors:  Stephanie E Brock; Beatriz E Rendon; Dan Xin; Kavitha Yaddanapudi; Robert A Mitchell
Journal:  PLoS One       Date:  2014-06-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.